Thermo Fisher Scientific Inc. (TMO) has seen a significant gain of shares among various investment firms.
Voya Investment Management LLC and
Signal Advisors Wealth LLC have notably increased their holdings in the company.
Morgan Stanley and
J.P. Morgan are maintaining a bullish stance with the latter maintaining a buy rating and a target price of $675. The company's stock performance has sparked renewed interest, particularly considering its recent initiatives in biotechnology such as the expansion of its Alzheimer’s registry.
Wells Fargo has upped its price target on TMO from $635 to $675. Thermo Fisher's
promo bioprocessing network in Asia may be a game changer for the firm's investment case.
Thermo Fisher has raised €2.1 billion through floating and fixed-rate senior notes.
Goldman Sachs initiated coverage of TMO with a buy recommendation, further fueling the company's positive outlook. Notably, the company has beat Q3 expectations with a 5% rise in revenue. Concerns about the company's valuation persist, however, as some analysts and investors find the stock price not quite adding up.
Thermo Fisher Scientific TMO News Analytics from Tue, 02 Sep 2025 07:00:00 GMT to Sat, 20 Dec 2025 13:40:06 GMT -
Rating 8
- Innovation 7
- Information 9
- Rumor 2
